Available Until 12/31/2024

Biosimilar Operational Readiness: Current and Future Market Landscape

Course Description: 

Biologics, used for decades to treat chronic inflammatory conditions, have substantially improved patient outcomes. While incredibly valuable, they are also a significant proportion of health care spend in the United States. Many biologics for rheumatology and chronic inflammatory diseases will lose patent protection over the next three years, a move analysts predict will precipitate a substantial shift in this expanding global market valued at $382 billion in 2022.

Biosimilars, “highly similar to” and without “clinically meaningful differences from” the reference biologic agents, are expected to decrease the overall cost burden to the health care system. Initial trends indicate relatively slow adoption of biosimilars, with more encouraging utilization of these products compared to reference biologics since 2020.Attention now shifts to considerations for a competitive market. Payers, stakeholders in adopting biosimilars, need education on biosimilar concepts, policies and regulations, clinical evidence, and market trends to prepare and provide timely access to newly launched and pipeline treatment options.

This session will discuss the current state of biosimilars and what to expect in the future.

Learning Objectives:

At the completion of this activity, participants should be able to:
  1. Define biosimilar concepts from a managed care perspective, including utilization trends, market competition, access, interchangeability, switching, and substitution.
  2. Discuss evidence-based formulary considerations for the current biosimilar market, anticipated launches, and pipeline for chronic inflammatory diseases.
  3. Summarize strategies managed care professionals can utilize to improve education and adoption of biosimilars among key stakeholders.


Timothy Mok, PharmD, BCPS, BCOP 

Hematology Oncology Pharmacy Research Analyst

Kaiser Permanente

Livermore, CA

Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA

Director, Pharmacy Cancer Care

Mayo Clinic

Rochester, MN


Shahsa Moghimi, PharmD

Sr Clinical Advisor

CVS Caremark

Chanhassen, Minnesota


The Academy of Managed Care Pharmacy (AMCP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

ACPE UAN:0233-0000-23-005-H01-P • Activity Type: Knowledge-Based
Contact Hours: 1.25
Release Date: March 22, 2023 •  Expiration Date: December 31, 2024
Activity Fee: Free for Members and $30 for Non-Members

Participants should claim continuing pharmacy education (CPE) credit for this home study activity only if they have not claimed credit for the live activity presented at AMCP 2023. CPE credit will be processed through the AMCP Learn portal and reported directly to CPE Monitor. Please allow 72 hours for processing and posting in your NABP account.

To receive credit for an online activity you must:

  • Review the full content of the activity.
  • Successfully complete the post-test (required to pass with a score of 70% or higher, it may be taken a maximum of three times).
  • Complete a specific activity evaluation.

System Technical Requirements/Viewing Requirements:

System Requirements Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating websites. View the minimum technical and system requirements for continuing education online learning activities.

Credit Information

Activity Number Credit Amount Accreditation Period
ACPE UAN #0233-0000-23-005-H01-P 1.25 Contact Hours March 22, 2023 - March 22, 2026